Skip to main content

Table 1 Patients’ characteristics

From: Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study

 

No. of patients (%) a

 

Variable

Gefitinib

Erlotinib

P

 

(n = 102)

(n = 95)

 

Age (years)

 Median [range]

73 [37–90]

68 [37–87]

0.001 c

 < 75

60 (59)

78 (82)

< 0.001 d

 ≥ 75

42 (41)

17 (18)

 

Sex

 Male

46 (45)

50 (53)

0.180 d

 Female

56 (55)

45 (47)

 

ECOG PS

 0–1

86 (84)

84 (88)

0.417 d

 2–3

16 (16)

11 (12)

 

Stage

 I - III

49 (48)

36 (38)

0.195 d

 IV

53 (52)

59 (62)

 

BSA (m2)

 Median [range]

1.5 [1.1–1.9]

1.6 [1.1–2.0]

0.045 c

 <  1.6

70 (69)

54 (57)

0.105 d

 ≥ 1.6

32 (31)

41 (43)

 

BMI (kg/m2)

 Median [range]

21.7 [14.9–31.3]

22.0 [15.3–30.3]

0.796 c

 < BMI 25

83 (81)

81 (85)

0.568 d

 ≥ BMI 25

19 (19)

14 (15)

 

Recurrence

 Yes

41 (40)

34 (36)

0.559 d

 No

61 (60)

61 (64)

 

Metastasis

 Yes

91 (89)

88 (93)

0.465 d

 No

11 (11)

7 (7)

 

Treatment line

 First line

59 (58)

26 (27)

< 0.001 d

 Second line and later line

43 (42)

69 (73)

 

EGFR mutation

 Exon 19 Deletion

  Yes

44 (43)

34 (36)

0.311 d

  No

58 (57)

61 (64)

 

 Exon 21 L858R point mutation

  Yes

51 (50)

38 (40)

0.197 d

  No

51 (50)

57 (60)

 

Smoking history

 Yes

39 (38)

46 (48)

0.154 d

 No

63 (62)

49 (52)

 

Grade 1 Liver dysfunction b

 Yes

37 (36)

31 (33)

0.654 d

 No

65 (64)

64 (67)

 
  1. a Percentages are rounded off
  2. b Any of AST, ALT, T-Bil, or ALP grade 1 as evaluated by CTCAE version 5.0 at the start of treatment
  3. c Mann-Whitney U test
  4. d Fisher’s exact test